Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1147 - miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Hsiang-lin Tsai


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


H. Tsai1, C. Huang2, W. Su2, K. Li2, J. Wang2

Author affiliations

  • 1 Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 807 - Kaohsiung City/TW
  • 2 Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 810 - Kaohsiung/TW


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1147


Vascular endothelial growth factor (VEGF) is correlated with angiogenesis and early relapse of colorectal cancer (CRC). This study investigated the role of miR-148a in the regulation of VEGF/angiogenesis and early relapse of CRC.


We established a stable clone with miR-148a expression in HCT116 and HT29 cell lines and created a hypoxic condition by using CoCl2 to determine the underlying mechanism of miR-148a. The effects of miR-148a on the pERK/HIF-1α/VEGF pathway were evaluated through western blotting, and the inhibitory effect of miR-148a on angiogenesis was demonstrated through a tube formation assay. Sixty-three CRC tissues (28 early relapse and 35 non–early relapse) were analyzed to assess the relationship between miR-148a and HIF-1α/VEGF.


The protein expression of pERK/HIF-1α/VEGF in HCT116 and HT29 cells was significantly decreased by miR-148a (all P < 0.05). The protein expression of VEGF/HIF-1α was strongly inversely associated with the expression of miR-148a in the 63 CRC tissue samples (all P < 0.05). Tube formation assay demonstrated that miR-148a significantly obliterated angiogenesis.


miR-148a suppresses VEGF through downregulation of the pERK/HIF-1α/VEGF pathway and might lead to the inhibition of angiogenesis; miR-148a downregulation increased the early relapse rate of CRC. This demonstrates that miR-148a is a potential diagnostic and therapeutic target.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.